Inj mogamulizumab-kpkc, 1 mg
Products billed under this code include Poteligeo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Poteligeo.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Poteligeo | Kyowa Kirin, Inc. | 42747-0761-01 | 20 | $5,170.72 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $258.536 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $258.536 | +$5.069 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $253.467 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $253.467 | +$4.97 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $248.497 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $248.497 | +$4.872 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $243.625 | +$0.435 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $243.19 | +$4.342 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $238.848 | +$0.32 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $238.528 | +$4.363 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $234.165 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $234.165 | +$6.821 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $227.344 | +$0.638 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $226.706 | +$5.984 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $220.722 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $220.722 | +$4.328 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $216.394 | +$0.145 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $216.249 | +$3.053 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $213.196 | +$0.561 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $212.635 | +$2.59 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $210.045 | $0.00 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $210.045 | +$3.104 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $206.941 | +$0.517 | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $206.424 | – | 1 MG | Inj mogamulizumab-kpkc, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.